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The  plasma  membrane  of  the  mouse  peritoneal  macrophage  has  specific 
receptors  which  enable  the cell  to ingest  antibody-coated sheep red .cells  and 
is also rich in a  divalent  cation-dependent adenosine triphosphatase  (ATPase) 
activity (1,  2). By fusing macrophages with  a  strain of mouse melanoma cells 
which lacks  these  receptors,  one  could not only trace  the fate  of the macro- 
phage membrane in the heterokaryons, but also hope to learn about the expres- 
sion of cell-specific traits in animal cells (3). 
Macrophage  homokaryons  obtained  by  Sendai  virus-induced  cell  fusion 
continued to exhibit  active phagocytosis of sensitized erythrocytes. The phago- 
cytic receptor could also be detected in heterokaryons shortly after fusion, but 
was progressively lost over the next 12-24 hr. The ATPase activity disappeared 
from heterokaryons as well, and in addition, seemed to spread out over the cell 
surface. 
Several  possible  mechanisms  could  account  for  these  observations.  These 
include mixing of membrane components resulting in dilution and loss of func- 
tion; endo- or exocytosis without further synthesis; and masking of the macro- 
phage  membrane  markers,  either  by  serum  factors  or  by  the  heterokaryon 
itself. We report experiments to distinguish  among these hypotheses. 
Materials and Methods 
Cell Culture and Cdl Fusion Technlque.--Carried out as described  (3). The macrophage 
phagocytic receptor was assayed with minor modifications of our previous procedure. Cover 
slip preparations were exposed at room temperature  for 15 rain to a 0.1% suspension of sheep 
red blood cells (SRBC) 1 which had been coated with a 1/~o00 dilution of a rabbit  anti-sheep 
* This work was partially  supported  by Grant AI 07012 from the National Institutes  of 
Health. 
1  Abbreviations used in this paper: AbSRBC, antibody-coated  sheep red blood cells; BGG, 
bovine gamma globulin; BSA, bovine serum albumin; EAT, Ehrlich ascites tumor cells; IgG, 
immunoglobulin  G; IPT-FCS, immunoprecipitin-tested  fetal  calf  serum;  NBCS,  newborn 
calf serum; 199 M, medium 199 +  10% NBCS; SRBC, sheep red blood cells; STI, soybean 
trypsin inhibitor. 
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red cell antiserum which contained mainly immunoglobulin G  (IgG) antibody. Assays were 
performed in the absence of complement. The cover slips were washed vigorously and incu- 
bated for 30 rain at 37°C in medium 199 (Microbiological Associates, Inc., Bethesda, Md.)  + 
10% newborn calf serum (NBCS) (hereafter 199 M). Cells were fixed with glutaraldehyde and 
stained with 0.1%  toluidine blue in 30%  methanol.  Ingested  and attached  red  ceils stain 
distinctively by this procedure.  100 cells were scored at random except where noted to the 
contrary. The mean number of red cells ingested per macrophage was used as an index of 
ingestion. In the present experiments the failure to ingest red ce]ls was associated with a failure 
in attachment. 
Reagents.--The  materials used in  these experiments were purchased  from  the following 
sources:  NBCS  and  immunoprecipitin-tested fetal  calf  serum  (IPT-FCS),  Grand  Island 
Biological Co., Grand Island, N.Y.; fraction V and bovine serum albumin (BSA), crystalline, 
Armour  Pharmaceutical  Co.,  Kankakee,  IlL;  Pronase,  Calbiochem,  Los  Angeles,  Calif.; 
disodium ethylenediaminetetraacetate (EDTA), Fisher Scientific Co., Fair Lawn, N.J.; bovine 
gamma globulin (BGG), Pentex Biochemical, Kankakee, Ill.; neuraminidase, cholera vibrio, 
500 units/ml, Behringwerke AG, Marburg-Lahn, West Germany, supplied by Certified Blood 
Products,  New  York; neuraminidase  (Clostridium  perfringens,  1 unit/rag),  soybean trypsin 
inhibitor  (STI)  (twice crystalline), and  bovine submaxillary mucin,  Sigma  Chemical  Co., 
St. Louis, Mo.; trypsin (twice crystalline), chymotrypsin, papain, ~-glucosidase (3.1 units/rag), 
and/3-galactosidase (320 units/rag), Worthington Biochemical Corp., Freehold, N.J. 
Enzyme and  Chemical  Treatmen¢ oj Heterokaryons.--Fused  preparations were cultivated in 
medium 199 +  20% NBCS for 1-2 days till most phagocytic receptor activity had been lost. 
The cells were washed two to four times in  199 and  then treated with a  particular reagent 
for 30 rain at 37°C.  The reagent was removed and the cells then handled according to the 
morphologic effect of each form of treatment. The cells in this fusion system react differently 
to trypsin: melanoma cells round up and become detached; macrophages spread and resist 
detachment; heterokaryons show intermediate behavior (3).  If melanoma cells and hetero- 
karyons were not detached by treatment, the preparations were washed two to four times in 
199  and assayed  for  phagocytic  function;  if  detachment  did  occur  the  cells  were  either 
incubated in sltu in 199 M  for 30-90 rain, until they reattached, or replated on new cover 
slips. In the latter case the detached cells were collected by gentle pipetting in 199 M, spun at 
1000 rpm for 5 min, and suspended in a small volume of 199 M for replating. Receptor activity 
was measured after 30-90 rain. 
Appropriate controls were set up for each treatment. A  trypsin solution was heated for 
10 min at 100°C to inactivate the enzyme. Neuraminidase activity was assayed in 199  and 
in 0.1 ~  acetate buffer, pH 5.0, with bovine submaxillary mucin as substrate. Free slalic acid 
was measured by the procedure of Warren (4). 
25 1:1 heterokaryons and  100 macrophages were scored in duplicate for attachment and 
ingestion of antibody-coated sheep red blood cells  (AbSRBC). Melanoma cells were always 
negative. 
The Role of Serum Factors in Receptor Loss.--Heterokaryons were prepared after cultivating 
macrophages in 199 +  15% IPT-FCS for 1 day.  1 hr after fusion cover slips were  placed in 
either 199 +  15% IPT-FCS,  199 +  1% BSA, or 199 +  1%  fraction V. Receptor  function 
was measured 4 and 20 hr after fusion. Some preparations were assayed  after trypsin  treat- 
ment, 100 #g/ml for 30 mix at 37°C. 
In another set of experiments the fused cells were incubated in nonspeciflc BGG. 1 hr after 
fusion groups of cover slips were placed in 199 plus one of the following: 20% NBCS,  20% 
IPT-FCS, 20% IPT-FCS  +  1 mg/ml BGG, or 20% IPT-FCS  +  10 mg/ml BGG. Receptor SAIMON GORDON AND  ZANVIL COHN  949 
activity was assayed 2,  9,  and 21  hr after fusion. Before the assay the preparations were 
washed four times with 199  to remove free BGG. 
The Role  of Pro~eln and  RNA  Synthesis  in Receptor Loss.--Cycloheximide  and  bromo- 
tubercidin were used to inhibit protein and RNA synthesis, respectively (5, 6). 
Cells were exposed to cycloheximide, 5/~g/ml, from 1 hr after fusion. After 4-8 hr treatment 
the cover slips were washed three times in  199  and  phagocytic function assayed immedi- 
ately, or at a later time. 
Treatment with bromotubercidin, 5 ~ug/ml, was started before or after fusion. Bromo- 
tubercidin was present during fusion when necessary. 
Irradiation  with  Ultraviolet Light before Fusion.--Macrophages and  melanoma ceils were 
cultivated in 60-mm Falcon plastic tissue culture dishes (Falcon Plastics, Los Angeles, Calif.) 
for 1 day. The cells were washed twice, covered with 1 ml of 199, and irradiated for 10-90 
sec at a distance of 20 cm with a Sylvania germicidal lamp (G 15T8). After irradiation the cells 
were washed and incubated in 199 M. The preparations were fused 1-2 hr after ultraviolet 
light treatment and then incubated in medium 199 +  20% NBCS until ready for assay of their 
receptor activity. 
Macrophage Fusion with D~erent Cdls.--Red  blood cells were obtained from 12-day  old 
chick embryos (5). Fibroblast primary cultures were prepared from chick embryos (7). Ehrlich 
ascites tumor (EAT) cells were provided by Dr. E. Borenfreund, Sloan-Kettering Institute, 
New York. The ascites tumor was passaged in NCS mice and harvested 4-5 days after inocu- 
lation. 1 X  104-1 X  106 of these cells were pipetted onto macrophage monolayers. After 1 hr 
the preparations were treated with  1000 hemagglutinating units of ultraviolet-inactivated 
Sendai virus (3). The cover slips were washed 30-60 rain later and placed in medium 199 + 
20% NBCS. Phagocytic function was assayed at intervals. 
Many of the chick red cells and most of the EAT cells which did not fuse with macrophages 
were washed away subsequently. The macrophages ingested the other unfused red cells so that 
pure populations of macrophages and heterokaryons remained after 1 day. The EAT cells 
did not attach to glass or grow in vitro unless they had fused with a macrophage. All hetero- 
karyons were identified on the basis of nuclear morphology. 
RESULTS 
The  Recovery of  Phagocytic Function by  Heterokaryons.--Heterokaryons 
which lacked phagocytic receptor activity after cultivation for 2 days immedi- 
ately recovered full receptor function upon treatment with trypsin (Figs.  1, 
3 a). If such heterokaryons were then cultivated further in fresh serum-contain- 
ing medium, the receptor once more became undetectable. The extent of re- 
covery of receptor activity depended on the concentration of trypsin employed 
(Table I). Full recovery occurred after treatment with 1-10 ~g/ml trypsin for 
30 rain at 37°C. These changes in heterokaryon receptor activity were brought 
about without change in phagocytosis by unfused macrophages present in the 
same preparation. 
Control  experiments  were  performed  to  exclude  a  sampling  artifact,  in 
which  trypsin  treatment could have selected a  population of heterokaryons 
rich in macrophage receptor activity. Trypsin treatment was limited to brief 
periods  at room temperature  (Table II).  Receptor  activity reappeared  after 950  MACROPHAGE-MELANOMA  CELL  HETEROKARYONS.  IV 
treatment with  2 #g/ml trypsin for 6  rain,  at which  time heterokaryons had 
not  yet  become detached  from glass.  In  another  experiment  all  the  hetero- 
karyons were deliberately detached  from cover slips  by treatment  with  100 
#g/ml trypsin for 30 rain at 37°C and then replated on a fresh cover slip. This 
population of heterokaryons also recovered full receptor activity. 
Trypsin treatment  did  not  alter  the  specificity of  the  interaction  between 
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FI6, 1.  Recovery of the phagocytic receptor in heterokaryons. Trypsin treatment  2 days 
after fusion (arrow). 
antibody-coated red  cells  and  macrophage receptor.  Melanoma cells  did  not 
bind  any AbSRBC  after  trypsinization  and  antibody  on  the  red  cell  was 
obligatory for attachment as well as ingestion. 
1-2-day  old  heterokaryons lacking  demonstrable  phagocytic activity were 
subjected  to a  variety of chemical and enzymatic treatments,  summarized in 
Table  III.  These  experiments  demonstrated  clearly  that  proteolysis  was 
necessary to recover receptor activity. Heat inactivation of the trypsin or the 
presence of soybean trypsin inhibitor prevented its effect. Different proteolytic 
enzymes like pronase, chymotrypsin, and papain were as effective as trypsin. 
Treatment with EDTA,  on the other hand,  was ineffective at concentrations 
which  detached  heterokaryons from the glass. Neuraminidase  treatment  was SALMON  GORDON  AND  ZANVIL  COHN 
TABLE  I 
The Effect of Trypsin  Treatment on the Ingestion of Antibody-Coated  SRBC* 
951 
Treatment  Ratio heterokaryon  :  (~g/ml trypsin)  Time after treatment  ! :1 Heterokaryons  Macrophages  macrophage X  100 
hr 
Control  --24 
10 
0.1 
3.2  6.6  50 
2.7  6.6  41 
0.5  2.4  8.2  29 
1.2  7.1  17 
3  1.6  6.7  24 
24  1.1  6.3  17 
1.0  5.7  18 
48  0.55  9.3  5 
0.5  5.4  5.3  102 
5.9  6.6  90 
3  5.8  5.6  104 
24  2.2  4.8  46 
3.8  6.5  58 
48  0.80  6.0  13 
0.36  5.4  7 
0.5  6.1  6.6  93 
4.9  6.5  76 
3  5.0  7.0  70 
4.5  6.1  75 
24  3.5  6.5  54 
2.8  6.8  41 
48  0.5O  7.0  7 
0.5  3.2  6.0  53 
2.1  6.1  34 
3  2.3  6.8  34 
24  2.0  6.8  30 
1.8  7.4  24 
* Trypsin  treatment  2  days  after  fusion for  30  min  at  37°C.  Incubated  in  medium 
199 -4- 15% NBCS after treatment. SRBC coated with 1/2000  antiserum. Assayed in situ, in 
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also  ineffective.  Control  experiments  confirmed  that  when  the  enzyme was 
used in medium 199  it retained  77 %  of its activity in acetate buffer, pH 5.0. 
These findings gave rise to the hypothesis that proteolytic treatment removed 
or altered surface protein(s) which had masked receptor activity and that the 
receptor could  again become masked during  subsequent  in  vitro cultivation. 
The Role of Serum Factors in Blocking the tteterokaryon Phagocytic  Receptor.- 
Masking  proteins  could  have been  adsorbed  directly from the  serum in  the 
culture medium or synthesized by the heterokaryon itself. In the former event 
the  adsorbed  proteins  could  be  nonspecific  gamma  globulins  or  some  other 
serum proteins. 
TABLE II 
In Situ Unmasking of 1  :  1 tteterokaryons after Brief Trypsin Treatment* 
Concentration  Duration of treatment  Mean No. AbSRBC ingested 
eg/rnl  Min 
5  2  0.2 
4  0.9 
6  3.3 
8  6.3 
2  0.8 
4  0.8 
6  4.4 
8  3.2 
* Trypsin treatment  2 days after fusion at room temperature. Washed three times and 
assayed immediately. 
Cells were therefore cultivated in the absence of gamma globulin or placed 
in  a  medium in  which  BSA was the  only protein.  In  all cases  (Table IV a) 
receptor activity dropped to  15-30%  of the initial  activity in 20 hr and this 
effect could be reversed by treatment with trypsin. 
In  other  experiments nonspecific BGG was  added  to  the  culture  medium 
~fter fusion  (Table IV b). This experiment showed that the rate of disappear- 
ance of the phagocytic receptor could be slightly accelerated by adding large 
quantities  of BGG  (10  mg/ml)  to  the  medium,  but  was  not  a  prerequisite 
for its loss. It was therefore concluded that serum proteins were not the major 
cause of the blocked receptors. 
The  Effect  of  Inhibitors  on  Receptor  Disappearance.--If  the  heterokaryon 
made the proteins which  blocked the phagocytic receptor,  could this process 
be prevented? SAIMON GORDON AND  ZANVIL COHN  953 
An experiment in which cycloheximide was used to block protein synthesis 
after  fusion is illustrated in Fig.  2.  Unlike the  control preparation in which 
receptor activity was lost, the cyclohexmide-treated heterokaryons maintained 
full phagocytic  activity. Receptor activity in the  unfused macrophages  was 
also unaffected by cycloheximide treatment. When the block in protein syn- 
TABLE III 
The Effect of Chemical and Enzymatic Treatments  on Masked Heterokaryons* 
Ingestion  of AbSRBC  Ratio heterokaryons  :  Treatment  1:1 Heterokaryons~  Macrophages~  macrophages  X 100 
Nil  0.60  6.3  10 
Trypsin (5 #g/ml)  4.3  5.5  78 
Heat inactivated  0.78  7.8  10 
+12 #g/ml STI  0.52  9.6  ~  5 
+6 #g/ml STI  1.3  7.0  19 
Pronase (10 #g/ml)  9.8  8.8  111 
Chymotrypsin (10 #g/ml)  5.3  6.5  82 
Papain control (medium 199 +  0.01 M  1.5  6.5  23 
cysteine HC1) 
Papain (10 #g/ml) (in medium 199 +  6.0  6.1  99 
0,01 M cysteine HC1) 
EDTA control (Ca, Mg-free buffer)  0.95  6.0  18 
EDTA 5.4 X 10  -4 ~  1.2  9.9  12 
1.1  7.3  11 
Neuraminidase,  C.  vibrio  (100 units/  1.8  7.9  23 
ml) 
C. perfringens  (1 unit/ml)  1.1  N.D.  -- 
/3-Galactosidase (10 #g/ml)  0.85  6.2  14 
/~-Glucosidase (500 #g/ml)  0.80  7.2  11 
* Fused preparations  cultivated  in medium 199 +  20% NBCS for 1 day, washed twice, 
and treated  for 30 min at 37°C with appropriate  reagent. Assayed, in situ, 0-90 min after 
treatment. 
Mean for 25 heterokaryons. 
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TABLE  IV 
(a)  The Masking Reaction in the Absence of Serum Factors 
4Hr after fusion  Uptake of AbSRBC by 1:1 
heterokaryons 20 hr after fusion 
Medium  No trypsin  Trypsin 
Mean  SE 
Mean  SE  Mean  sE 
199 +  15% IPT-FCS  13  1.5  3.0  0.57  12  2.0 
199 +  1% fraction V  15  1.5  2.1  0.54  16  3.3 
199 -J- 1% BSA  14  1.8  4.3  0.90  13  2.0 
(b)  The Effect of Incubation in Nonspecific BGG on the Ingestion of AbSRBC by 1:1 
Heterokaryons 
IPT-FCS  IPT-FCS  Time after fusion  NBCS Control  IPT-FCS  +1 rag/m] BGG  +10 mg/ml BGG 
hr 
2  7.9  --  --  -- 
9  1.8  4.0  3.5  1.5 
21  0.64  1.4  0.75  -- 
I  Cycloheximide  ] 
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Fie. 2.  The requirement for protein synthesis to mask the phagocytic receptor in hetero- 
karyons. 
thesis was reversed by washing out the drug, receptor activity was lost subse- 
quently and could again be uncovered with trypsin. 
In  another experiment cells were treated with  cyeloheximide for different 
periods of time and the reversible inhibition of masking studied in more detail SAIMON  GORDON  AND  ZANVIL  COHN  955 
(Table V). Receptor activity could be maintained for 8 hr in the presence of 
cycloheximide. Removal of the drug after 4 or 6 hr resulted in loss of receptor 
activity at a rate similar to that of the untreated control, with a half-life of the 
order of 3 hr. The cycloheximide effect was still reversible after an 8 hr treat- 
ment, but with a 2 hr lag period. 
Some  unfused  macrophages  are  killed  by  6-8  hr  continuous  exposure  to 
cycloheximide,  but  heterokaryons  and  melanoma  cells  are  able  to  survive. 
Even an 8 hr treatment with cycloheximide does not interfere with phagocytosis 
in active heterokaryons (Fig. 3 b) or surviving macrophages. 
Preparations were also treated with cycloheximide for 6-8 hr, starting 20 hr 
after fusion,  to see if the  receptor  could  be uncovered by inhibiting protein 
TABLE V 
The Reversible Inhibition of Masking by Cycloheximide* 
Mean No. AbSRBC ingested  by 1:1 heterokaryons 
Time after fusion 
Control  CH 1-5~  CH 1-7  CH 1-9 
hr 
1  5.6  --  --  -- 
5  3.4  5.0  --  -- 
7  3.0  3.4  6.3  -- 
9  2.1  1.7  4.2  6.4 
11  0.9  1.3  2.5  7.6 
22  --  --  --  2.2 
* Groups of cover slips treated with 5 #g/ml cycloheximide  for 4, 6, or 8 hr starting  1 hr 
after fusion. The cells were then washed three times, incubated in medium 199 +  20% NBCS, 
and assayed at different times. 
$ Cycloheximide treatment  1-5 hr after fusion. 
synthesis  after the period of masking. Receptor activity remained masked in 
this  experiment.  This  meant  that  cycloheximide treatment,  per  se,  did  not 
bring about increased receptor activity in the heterokaryons, but that protein 
synthesis had to be blocked during the period immediately after fusion. 
The role of RNA synthesis in masking the receptor was investigated next, 
using  bromoturbercidin  as  a  reversible  inhibitor  (Table  VI).  When  hetero- 
karyons were treated with bromotubercidin 1-9 hr after fusion, there was no 
effect on masking,  whereas cycloheximide treatment  during  the  same period 
prevented masking (Table VIa). If, however, bromotubercidin treatment was 
started 2 hr before fusion, masking was effectively prevented (Table VI b). This 
inhibition of masking was reversible after 12 hr treatment (Table VI c). 
Ultraviolet  Irradiation  of Cells  before Fusion.--Melanoma  cells  and  macro- 
phages  were  irradiated  with  ultraviolet  light  before  fusion  to  separate  the 
contribution of each heterokaryon to the masking reaction. The effect of such FIG. 3.  Uptake of AbSRBC by heterokaryons under a variety of conditions. (a)  A 2 day 
old  heterokaryon ingests numerous red  cells  after treatment with  trypsin to  unmask  the 
phagocytic receptor. Phase-contrast,  )< 800. (L)  A  9  hr  old  heterokaryon displays active 
ingestion of red cells after 8 hr treatment with cycloheximide to prevent masking. Hetero- 
karyons are tj~29ically well spread after such treatment. Stained preparation. )< 1500. 
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treatment  is  shown  in  Table  VII.  Melanoma  cell  pretreatment  preserved 
phagocytic function in heterokaryons, whereas macrophage pretreatment had 
no effect on receptor loss. 
Both cell fusion and phagocytic activity were unaffected by ultraviolet pre- 
treatment. Similar results were obtained after pretreating the cells for longer 
TABLE VI 
The Requirement  for RNA Synthesis to Mask the Fc Receptor in 1:1 Heterokaryons 
(a) Bromotubercidin (BT) treatment 1-9 hr after fusion 
Ingestion of AbSRBC 
Time after fusion 
Control  Cycloheximide*  Bromotubercidin treatment 
hr 
2.5  9.0  --  -- 
5  3.2  10.2  4.7 
9  1.7  8.1  2.8 
(b) Continuous bromotubercidin treatment started before, or after, fusion 
Ingestion of AbSRBC 
Time after fusion  BTstarted 2 hr  BTstarted 0.5 hr  BTstarted 2 hr 
Control  after fusion  after fusion  before fusion 
hr 
2  7.0  --  --  9.7 
7  1.8  2.8  3.8  8.2 
(c) The reversible inhibition  of masking by bromotubercidin treatment 
Ingestion of AbSRBC 
Time after fusion  Bromotubercidin treatment 
Control  (started 5 hr before fusion) 
hr 
2  5.8  5.1 
5  3.0  6.4 
7  2.4  Washout BT  7.4 
23  1.0  1.5 
* Cycloheximide treatment 1-9 hr after fusion. 
periods  (30  or 90 sec),  although many irradiated cells were then dead  1  day 
later. 
The Role of Macrophage  Partner in the Masking Reaction.--Studied to deter- 
mine if this process was unique to fusion with melanoma cells. As shown in 
Table  VIII,  fusion  with  Ehrlich  ascites  tumor  cells  caused  heterokaryon 
receptor activity to disappear even more rapidly. Macrophage-chick erythro- 
cyte heterokaryons on the other hand maintained their receptor activity for 7 958  MACROPHAGE-MELANOMA CELL  HETEROKARYONS.  IV 
TABLE VII 
The Effect of Ultraviolet Irradiation  before Fusion on the Ingestion  of AbSRBC by 
Heterokaryons* 
1:1 Heterokaryons  Ratio[heterokary- 
Fusion  Time after fusion  Mean  SE  ons :macrophages 
Control 
hr 
3  10.5  1.3  1.05 
9  6.6  1.6  0.67 
21  1.8  0.62  0.20 
Ultraviolet-treated  3  11.0  1.0  1.3 
melanoma cells  9  9.5~  0.71  1.3 
21  7.3§  0.74  0.82 
Ultraviolet-treated  3  9.9  1.0  1.0 
macrophages  9  5.0  1.0  0.65 
21  1.8  0.36  0.23 
* Cells were irradiated for 10 sec at 20 cm distance. 
:~t  =  1.737, P  <  0.05. 
§ t  =  3.6066,  P  <  0.0025. 
TABLE  VIII 
The Role of Fusion Partner on the Ingestion  of AbSRBC by 1:1 Macrophage 
H eter  o  kar  yons 
Type of macrophage heterokaryon  Time after fusion  Ratio heterokaryon  : 
macrophage X  100 
Melanoma cell 
Ehrlich ascites tumor cells 
Primary chick fibroblast 
12 day chick erythrocyte 
/17 
20  15 
20  0 
3  83 
20  49 
45  42 
70  37 
20  100 
45  80 
120  105 
168  90 
days.  After fusion  with  primary  chick fibroblasts,  an  intermediate  result  was 
obtained  and receptor activity diminished only gradually. 
DISCUSSION 
The  experiments  with  trypsin  and  inhibitors  of  protein  synthesis  suggest 
that masking of the macrophage receptor is a  major cause of the loss in phago- SAIMON  GORDON  AND  ZANVIL  COHN  959 
cytic  function  in  heterokaryons.  Additional  membrane  changes  probably 
accompany the fusion of two cells which differ in their membrane properties. 
These include the spreading out and intermixing of surface enzymes (3)  and 
antigens (8) and, perhaps, other dynamic changes in the synthesis and turnover 
of membrane components. The use of inhibitors in such a system could therefore 
bring about complex changes and their effect should be interpreted with great 
caution. Our ignorance of the chemical nature of the macrophage receptor (1) 
introduces further uncertainty. However, the stability of the receptor during 
trypsinization and inhibition of protein or RNA synthesis made it a particularly 
useful membrane marker for the present studies. 
Macrophages may carry adsorbed gamma globulin on their plasma membrane 
(9)  and trypsin treatment, which has been reported to enhance phagocytosis, 
could remove such antibody from the cell surface  (1).  In the present studies 
the loss and recovery of receptor function by trypsin treatment did not require 
the presence of serum factors. Moreover, the membrane proteins responsible 
for masking could be regenerated after trypsin treatment. Masking occurred 
as rapidly after reversal of protein synthesis inhibition as after fusion without 
inhibitor treatment  (3).  The masking process was prevented by inactivating 
the melanoma nucleus with ultraviolet light or by substitution with an inert 
chick red cell  nucleus  (10).  The melanoma nucleus was  therefore ultimately 
responsible for masking the macrophage membrane receptor as well as inducing 
macrophage DNA synthesis (6). 
The masking reaction could be because of direct steric hindrance of receptors, 
but more complex conformational changes in membrane structure are of course 
possible. The insertion of new melanoma proteins into the heterokaryon mem- 
brane could, for example, displace the macrophage receptor into crypts which 
are then inaccessible to the sensitized red cells. The masking proteins probably 
belong  to  the  melanoma cell  coat  since  they  are  susceptible  to  proteolytic 
digestion, without loss of cell viability. Mild digestion with enzymes has been 
used to unmask several cell surface receptors and antigens in a similar fashion. 
Proteases have been used to augment or reveal red cell antigens (11)  as well 
as cell receptors which react with plant lectins like wheat germ agglutinin (12) 
or  concanavalin  A  (13).  Similarly,  SV  40-transformed  tumor  cells  possess 
surface  (S)  antigens which become demonstrable in untransformed cells  after 
mild proteolytic treatment (14). 
Neuraminidase did not reactivate macrophage receptor  activity, although 
it may enhance nonspecific phagocytosis (15)  and perhaps unmask "immuno- 
genicity" in malignant cells or trophoblast (16, 17). This failure was not because 
of the use of inactive enzyme. 
The  ability to mask the macrophage receptor is not unique to melanoma 
cells  since Ehrlich ascites tumor cells  masked phagocytic function in hetero- 
karyons  even  more  rapidly.  Ehrlich  ascites  tumor  cells  also  suppress  the 
antigens of different cells  after hybridization  (18,  19),  perhaps  by a  similar 960  MACROPHAGE-MELANOM-A CELL  HETEROKARYONS.  IV 
masking  mechanism.  Fusion  between  macrophages  and  embryonic  chick 
fibroblasts brought about a very slow decline in receptor activity. More cells 
have, to  be  tested  to  determine if the  masking property  is  associated with 
malignancy, rate of cell growth, or cell maturity. 
It is interesting to compare the present findings with those made in chick 
erythrocyte-mouse fibroblast heterokaryons (20). The kinetics of disappearance 
of chick species antigens from these heterokaryons resembles that of the macro- 
phage receptor and ultraviolet irradiation of the chick red  cell before  fusion 
also failed to prevent its disappearance.  This process  also  depended on cell 
metabolism since incubation at lower temperature delayed the loss  of antigens. 
It  is  unlikely, however,  that  this  loss  was  because  of masking,  since  these 
antigens reappear spontaneously and accumulate progressively.  Do  these  two 
heterokaryon systems differ because of the particular receptor under study or 
because of the cells involved? Both possibilities can be tested. 
It is not known if material has to be removed from the heterokaryon surface 
to achieve unmasking or whether cleavage of particular peptide bonds brings 
about a  reorganization in membrane structure similar to that postulated for 
the unmasking of wheat germ  agglutinin receptors  (12).  Studies with these 
receptors suggest that such differences in membrane structure could play an 
important part in regulating cell growth (21). In addition, the masking reaction 
has potential significance in tumor-host relationships (22). Patients with tumors 
often have  circulating antibodies which enhance tumor  growth by masking 
tumor antigens (23).  The macrophage heterokaryons illustrate another mech- 
anism by which a tumor cell could alter its membrane properties in such a way 
that it would escape  immunologic surveillance  (24).  Tumor  cells  which can 
diminish their antigenicitity would be expected to have considerable selective 
advantage in vivo and a masking phenomenon could also be invoked to explain 
tumor progression. 
SITMMARY 
Mouse peritoneal macrophages possess a specific plasma membrane receptor 
for antibody-coated particles. Sheep red cells coated with rabbit  7S antibody 
attach readily to the macrophage surface and are subsequently interiorized. The 
fusion  of  macrophage  with  nonphagocytic mouse  melanoma cells  produces 
heterokaryons in  which the macrophage receptor is drastically  altered.  The 
receptor is present shortly after fusion and heterokaryons are actively phago- 
cytic. The ability to bind and ingest red cells is, however, progressively lost 
over the next 12-24 hr and does not reappear thereafter. 
Exposure  of heterokaryons to  trypsin  (1-100  #g/ml  for 30  rain  at  37°C) 
results in the reappearance of initial receptor activity and the unmasking of 
the surface receptor. This property is again lost upon subsequent cultivation. 
The masking process takes place when cells  are cultivated in the absence of SAIM~ON  GORDON  AND  ZANVIL  COItN  961 
IgG so that the adsorption of antibody from the medium is not responsible for 
this  phenomenon.  Inhibition  of  heterokaryon  protein  synthesis  preserves 
phagocytic activity in a reversible tashion and prevents the masking of macro- 
phage receptors.  Inhibition of melanoma RNA synthesis before fusion is also 
able  to  block  subsequent  masking,  but  is  ineffective  if  delayed  until  after 
fusion.  Ultraviolet  irradiation  of  the  melanoma  cell  before  fusion  prevents 
subsequent  masking,  whereas  similar  treatment  of  the  macrophage  has  no 
effect. 
Cells  differ markedly in  their  ability  to  mask the  macrophage phagocytic 
receptor  after  fusion.  Ehrlich  ascites tumor  cells mask the  receptor  rapidly, 
primary chick fibroblasts minimally, and embryonic chick erythrocytes not at 
all. 
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